NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences is a biopharmaceutical company that discovers, develops, and commercializes therapies for neurological, psychiatric, endocrine, and immunological conditions. Its commercial portfolio features INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, alongside CRENESSITY for classic congenital adrenal hyperplasia. The company also collaborates on therapies for endometriosis and uterine fibroids. In the United States, Neurocrine Biosciences sells its treatments through specialized distribution networks, serving customers that include specialty pharmacy providers, wholesale distributors, and specialty distributors.

The company operates commercially across the United States, supported by a specialized nationwide sales force of approximately 600 professionals. Its treatments also reach international markets, including Japan and select Asian territories, through collaboration and licensing arrangements where partner companies retain commercialization rights. Third-party logistics providers handle packaging, warehousing, and product distribution, while external contract manufacturers produce its commercial supply and clinical pipeline. The provided text does not state the location of the company's headquarters.

Summary of the business section of Neurocrine Biosciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“We have grown to a team of approximately 1,800 employees as of December 31, 2024, primarily employed in the U.S.”